.
GREENLEAF IN THE NEWS
01.21.09 The Gray Sheet
Former CDRH Director Daniel Schultz joins Greenleaf Health.
1.6.09 Former FDA Center Director Daniel Schultz
Joins Greenleaf Health as Senior Vice President
Greenleaf Health LLC today announced that Daniel G. Schultz, M.D., F.A.C.S., former Director of the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA), has joined the firm as Senior Vice President, Medical Devices and Combination Products.
11.16.09 University of Maryland Law School
Dr. Andrew Von Eschenbach serves as keynote speaker at University of Maryland School of Law’s National Conference on Emerging Issues in Food and Drug Law.
To watch Dr. von Eschenbach’s remarks,
11.08.09 Medical News Today
Dr. Andrew von Eschenbach delivers keynote address at 2009 Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS).
10.26.09 PharmAsia Summit
Dr. Andrew von Eschenbach addresses FDA’s Beyond our Borders program and what to expect from FDA in China and India, at the Windover PharmAsia Summit.
10.12.09 New Orleans Times-Picayune
Dr. Andrew von Eschenbach serves as keynote speaker at Loyola University New Orleans 2009 President’s Forum Series. Dr. von Eschenbach remarks address “Transforming Health Care in the 21st Century: The New Reality.”
News Release from Lola University New Orleans…
10.02.09 FDA Regulatory Symposium
Dr. Andrew von Eschenbach addresses the future of health care at the 2009 FDA Regulatory Symposium. To view Dr. von Eschenbach’s video remarks,
10.02.09 Dow Jones Newswire
Patrick Ronan comments to Dow Jones Newswire on the subject of off-label promotion.
07.05.09 Former FDA Deputy Chief of Staff Taryn Fritz Walpole Joins Greenleaf
Greenleaf Health LLC today announced that Taryn Fritz Walpole, who recently served as FDA Deputy Chief of Staff, has joined the firm as Vice President for Corporate Affairs.
07.01.09 FDLI.org
Click below for FDLI's home page where you will find a link to hear
Dr. von Eschenbach's speech given at the FDLI & FDA 52nd Annual Conference.
06.22.09 The Paper
“Transformation of Healthcare” will be the focus of a lecture presented by former Federal Food and Drug Administration Commissioner Andrew von Eschenbach at a program sponsored by The Friendship Center July 23rd.
06.11.09 POLITICO.com
Under the pretext of improving public health, the Senate is currently debating a bill that would give the Food and Drug Administration broad regulatory control over the tobacco industry. Andrew von Eschenbach, the former head of the FDA and also the former director of the National Cancer Institute and a cancer survivor, opposes the bill.
06.06.09 GAIBP Annual Conference
Dr. Andrew von Eschenbach delivers keynote address at Global Alliance of Indian Biomedical Professionals.
04.27.09 Milken Institute Global Conference 2009
Dr. Andrew von Eschenbach moderates panel discussion on wellness in the workplace at Milken Institute Conference. For complete video of panel discussion
03.03.09 BioWorld Today
"Biotech’s future is dependent on the new reality in
health care of integrating the parts and pieces of product
discovery, development and delivery," said former FDA
Commissioner Andrew von Eschenbach, who recently
joined Greenleaf Health LLC as a senior adviser.
03.02.09 Forbes.com
As a result of the Ketek controversy, the FDA division that handles antibiotics "is one of, if not the most, difficult, environments to work in at the agency right now," according to Patrick Ronan, a former FDA chief of staff who now consults for health care companies.
02.25.09 Former FDA Commissioner Andrew von Eschenbach, MD, Joins Greenleaf Health
Greenleaf Health LLC. today announced that Andrew C. von Eschenbach, MD, who recently stepped down as Commissioner of the Food and Drug Administration (FDA), has joined the firm as Senior Advisor.
Press Release
Related Articles
Former US FDA Chief to Advise Drug Makers - Reuters
Von Eschenbach Maps Out Role In Health Reform - In Vivo Blog
12.19.08 Associated Press
"Personally, I'm much more optimistic in what the FDA may look like a year or two from now in terms of the industry's ability to get products through," said Patrick Ronan, a former FDA chief of staff who now runs a food and drug consulting business.
11.19.08 The Wall Street Journal
"The FDA is a global regulatory body and expanding their footprint outside the U.S. is the first step in becoming more active in the global market,” Patrick Ronan, a former chief of staff at the FDA, tells the Health Blog.